Indigenous Bloom Hemp Corp. (VRTHF)

[NetworkNewsWire]

VRTHF's Cannevert Subsidiary Inks Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

Emerging pharmaceutical and IP development company Veritas Pharma (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) today announced that its research arm, Cannevert Therapeutics Ltd. (“CTL”), has signed a Material Transfer Agreement with the Institute for Medical Cannabis Corporation of Puerto Rico. Per the agreement, the Institute for Medical Cannabis will provide CTL with particular cannabis strains for upcoming human studies in the US territory. “We are pleased that Cannevert has identified a reputable producer that is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and conducting clinical research on its products. They will enable us to get medical grade strains of interest into the clinic and scientifically evaluated against different kinds of pain,” Veritas CEO Dr. Lui Franciosi stated in the news release.

To view the full press release, visit http://nnw.fm/Umo1K

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging pharmaceutical and IP development company, who, through its 80% owned subsidiary Cannevert Therapeutics Ltd. (“CTL”), is advancing the science behind medical cannabis. It is the company’s aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company’s commercial mission is to patent protect IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets. For more information, visit the company’s website at www.VeritasPharmaInc.com.